Core One Labs Announces Successful Proof of Concept and

VANCOUVER, British Columbia, Jan. 21, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLBF), (Frankfurt: LD6, WKN: A3CSSU) (“core one“or the”Society”) is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has optimized its recombinant production system (the “System“), successfully testing his proof of concept for psilocybin biosynthesis suitable for future large-scale use and has filed a patent application with the United States Patent and Trademark Office (“USPTO“) entitled “Production of psychedelic compounds » for the protection of his new psilocybin production system. Psilocybin is an extremely promising psychedelic compound in the treatment of addiction and depression.

The company’s team of scientists at Vocan have constructed optimized DNA sequences that can produce enzymes that mimic the biosynthetic pathway used by Psilocybe mushrooms. This allows bacteria to become psilocybin production factories. Led by Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, CEO of Vocan, Vocan scientists used DNA modeling to improve and optimize the design and produce unique DNA sequences that improve the efficiency and expression of these enzymes, allowing rapid and cost-effective production of psilocybin.

Currently, most companies use chemically synthesized psilocybin as the only cGMP product available in large quantities. The chemical process incurs significant costs and is less efficient compared to a biologically derived psilocybin. Vocan’s biosynthetic process retains the stereochemistry of natural psilocybin molecules found in magic mushrooms, which are known to have a more positive effect than the chemically synthesized counterpart. However, these tiny mushrooms are not an effective source of psilocybin because the amount produced is quite small and variable.

Vocan’s successful production system designs bacteria incorporating optimized biosynthetic genes from the Psilocybe fungus and other species and allows bacteria to act as a biological factory and synthesize psilocybin.

Additionally, the company’s team of scientists hypothesizes that by using a process of genetic mimicry and simple chemical modifications to enable the creation of bioidentical compounds, it is possible to produce other known and novel analogues of psilocybin and related psychedelics. Analogous compounds can potentially be more effective, targeted, and safer than natural compounds.

The patent application entitled “Production of psychedelic compoundsincludes claims that Vocan’s technology will enable the production of cGMP API-grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers and patients Vocan’s psilocybin production method will provide more affordable access to organizations looking to acquire cGMP API grade psilocybin Vocan’s psilocybin production method utilizes the well-established industrial fermentation process and can therefore be scaled up while consistently producing a high quality cGMP product.

I am very happy to say that we are keeping our promise to our shareholders and to the medical and research sectors in general that we have succeeded in producing biosynthesized psilocybin. Our team of scientists continues to achieve significant and amazing scientific milestones. Our goal is to play an important role in advancing research into mental health and the benefits of psychedelic drugs, and our cost-effective psychedelic compounds will go a long way toward enabling the widespread use of otherwise expensive drugs,said Dr. Hancock, Chairman of the Board and CEO of Vocan. “This successful proof of concept for the development and production of cost-effective, stereochemically sound psilocybin puts Core One in a very unique position. Not only does this potentially position the Company as the first company to commercialize a biosynthetic psychedelic, but it also positions us to become market leaders in terms of profitability.


Core One is a biotechnology research and life science technology company focused on bringing psychedelic drugs to market through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent-pending thin-film oral strip (the “Technology”) that dissolves instantly when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability . The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also has interests in medical clinics that maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for the disorders of mental health.

Joel Shacker
Chief executive officer

Email: [email protected]
Phone: 1-866-347-5058



The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the content of this press release.

The information in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. These factors include, among others: the risks and uncertainties associated with the Company’s limited operating history and the need to comply with stringent regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelic substances in the jurisdictions in which it operates. Although Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate the legalization of psychedelics for recreational use. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.

Comments are closed.